biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactati
Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 213
- Programs
- 7
- Drugs
- 14
- Patents
- 72
Oral MRT-2359
Phase 2 · small molecule · NSCLC
Oral MRT-2359 for NSCLC is a Phase 2 program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MRT-2359-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Monte Rosa Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- NSCLC
- Status
- active
- Trials
- 1